or Try an Advanced Search...

    Technical Analysis for ETNB - 89bio, Inc.

    Grade Last Price % Change Price Change
    F 7.76 -3.12% -0.25
    ETNB closed down 3.12 percent on Monday, July 1, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ETNB trend table...
    Date Alert Name Type % Chg
    180 Bearish Setup Bearish Swing Setup 0.00%
    NR7 Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Oversold Stochastic Weakness 0.00%
    Slingshot Bearish Bearish Swing Setup -3.12%
    Pocket Pivot Bullish Swing Setup -3.12%
    Volume Surge Other -3.12%
    Oversold Stochastic Weakness -3.12%
    Pocket Pivot Bullish Swing Setup 2.92%
    Lower Bollinger Band Touch Weakness 2.92%
    Older End-of-Day Signals for ETNB ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 6 hours ago
    Possible Inside Day about 6 hours ago
    Down 3% about 10 hours ago
    Down 2 % about 10 hours ago
    10 DMA Resistance about 10 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ETNB Chart by TradingView
    Basic chart:

    Profile

    89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Alcohol Hepatitis Steatohepatitis Metabolic Disease Non Alcoholic Fatty Liver Disease Innovative Therapies

    Is ETNB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 23 89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy
    May 22 89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
    May 14 89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
    May 10 89bio Inc (ETNB) Reports Increased Losses in Q1 2024 Despite Advancements in Clinical Trials
    May 9 89bio GAAP EPS of -$0.54 misses by $0.07
    May 9 89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
    May 9 ‘Jump on the Bandwagon,’ Says Bank of America About These 2 Stock Picks
    May 8 89bio to Participate in the BofA Securities 2024 Health Care Conference
    May 2 89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
    Apr 17 89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
    See more ETNB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 19.61
    52 Week Low 6.575
    Average Volume 1,047,669
    200-Day Moving Average 10.09
    50-Day Moving Average 8.55
    20-Day Moving Average 8.29
    10-Day Moving Average 8.06
    Average True Range 0.62
    RSI (14) 43.18
    ADX 13.88
    +DI 20.88
    -DI 26.37
    Chandelier Exit (Long, 3 ATRs) 8.11
    Chandelier Exit (Short, 3 ATRs) 8.85
    Upper Bollinger Bands 9.35
    Lower Bollinger Band 7.23
    Percent B (%b) 0.25
    BandWidth 25.66
    MACD Line -0.25
    MACD Signal Line -0.19
    MACD Histogram -0.062
    Fundamentals Value
    Market Cap 723.28 Million
    Num Shares 93.2 Million
    EPS -1.80
    Price-to-Earnings (P/E) Ratio -4.31
    Price-to-Sales 0.00
    Price-to-Book 1.92
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 8.32
    Resistance 3 (R3) 8.37 8.24 8.22
    Resistance 2 (R2) 8.24 8.10 8.21 8.19
    Resistance 1 (R1) 8.00 8.01 7.94 7.95 8.16
    Pivot Point 7.87 7.87 7.84 7.84 7.87
    Support 1 (S1) 7.63 7.73 7.57 7.58 7.36
    Support 2 (S2) 7.50 7.64 7.47 7.33
    Support 3 (S3) 7.26 7.50 7.30
    Support 4 (S4) 7.21